Akari Therapeutics extends April 2023 notes to Aug 2026, closes $500k tranche, reveals PH1 ADC data

Akari Therapeutics Plc

April 2023 notes maturity extended to Aug 31, 2026; conversion/exercise price amended to $0.81/ADS ($0.000405 per ordinary share).
Paid ~$81,700 accrued interest through Sep 30, 2025; default claims released.
Closed second tranche of August 2025 Notes: issued $625k principal for $500k; total $3.5M principal issued.
April 2023 warrants exp. extended to Aug 2030, 342,420 ADSs issuable; Series A warrants exp. extended to Apr 2030 for 4,891,272 ADSs.
Preclinical data: PH1 ADC suppresses AR-V7 in mCRPC model; plans to present at scientific conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.